CA2693141C - Use of a granulin or a granulin-like compound in the therapy or prophylaxis of neuropathic pain - Google Patents

Use of a granulin or a granulin-like compound in the therapy or prophylaxis of neuropathic pain Download PDF

Info

Publication number
CA2693141C
CA2693141C CA2693141A CA2693141A CA2693141C CA 2693141 C CA2693141 C CA 2693141C CA 2693141 A CA2693141 A CA 2693141A CA 2693141 A CA2693141 A CA 2693141A CA 2693141 C CA2693141 C CA 2693141C
Authority
CA
Canada
Prior art keywords
granulin
compound
molecules
progranulin
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2693141A
Other languages
English (en)
French (fr)
Other versions
CA2693141A1 (en
Inventor
Irmgard Tegeder
Gerd Geisslinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Goethe University Frankfurt
Original Assignee
Goethe University Frankfurt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goethe University Frankfurt filed Critical Goethe University Frankfurt
Publication of CA2693141A1 publication Critical patent/CA2693141A1/en
Application granted granted Critical
Publication of CA2693141C publication Critical patent/CA2693141C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2693141A 2007-07-16 2008-07-14 Use of a granulin or a granulin-like compound in the therapy or prophylaxis of neuropathic pain Expired - Fee Related CA2693141C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102007033359.7 2007-07-16
DE102007033359A DE102007033359B4 (de) 2007-07-16 2007-07-16 Verwendung eines Granulins oder einer Granulin-ähnlichen Verbindung zur Therapie oder Prophylaxe von chronischen Schmerzen
PCT/DE2008/001138 WO2009010045A1 (de) 2007-07-16 2008-07-14 Verwendung eines granulins oder einer granulin-ähnlichen verbindung zur therapie oder prophylaxe von chronischen schmerzen

Publications (2)

Publication Number Publication Date
CA2693141A1 CA2693141A1 (en) 2009-01-22
CA2693141C true CA2693141C (en) 2018-01-23

Family

ID=40014940

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2693141A Expired - Fee Related CA2693141C (en) 2007-07-16 2008-07-14 Use of a granulin or a granulin-like compound in the therapy or prophylaxis of neuropathic pain

Country Status (6)

Country Link
US (2) US8367616B2 (enExample)
EP (1) EP2178553B1 (enExample)
JP (1) JP5584618B2 (enExample)
CA (1) CA2693141C (enExample)
DE (1) DE102007033359B4 (enExample)
WO (1) WO2009010045A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009089635A1 (en) * 2008-01-16 2009-07-23 Neurodyn, Inc. Treating neurodegenerative diseases with progranulin (pgrn)
WO2010048710A1 (en) 2008-10-31 2010-05-06 Neurodyn, Inc. Neurotoxic sterol glycosides
WO2012045451A1 (en) 2010-10-05 2012-04-12 Ludwig-Maximilians-Universitaet Muenchen Novel therapeutic treatment of progranulin-dependent diseases
WO2018013775A2 (en) * 2016-07-14 2018-01-18 Emory University Granulin compositions and uses related thereto
BR112022012230A2 (pt) 2019-12-23 2022-08-30 Denali Therapeutics Inc Variantes de progranulina

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015195A1 (en) * 1992-02-03 1993-08-05 Samuel Solomon Granulins from leukocytes
JP2002335972A (ja) * 2000-06-07 2002-11-26 Ajinomoto Co Inc インスリン受容体関連受容体結合蛋白質及びその利用
US6872703B2 (en) * 2000-06-07 2005-03-29 Ajinomoto Co., Inc. Insulin receptor-related receptor binding protein
JP4488903B2 (ja) * 2003-02-26 2010-06-23 エイアンドジー ファーマスーティカル インコーポレイテッド Ｂ細胞の増殖を増加させる方法
US8071652B2 (en) * 2003-08-21 2011-12-06 The Board Of Regents Of The University Of Texas System Method of treating irritable bowel syndrome
JP4222614B2 (ja) * 2005-02-10 2009-02-12 独立行政法人科学技術振興機構 神経因性疼痛治療剤
WO2007000924A1 (ja) * 2005-06-28 2007-01-04 Osaka University プログラニュリン活性を抑制または促進する物質を含む医薬組成物、およびプログラニュリン活性を抑制または促進する物質のスクリーニング方法
JP5123936B2 (ja) * 2006-05-30 2013-01-23 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 認知症の検出および治療

Also Published As

Publication number Publication date
WO2009010045A1 (de) 2009-01-22
US8367616B2 (en) 2013-02-05
CA2693141A1 (en) 2009-01-22
US9655947B2 (en) 2017-05-23
DE102007033359B4 (de) 2010-12-02
EP2178553B1 (de) 2013-11-27
DE102007033359A1 (de) 2009-01-29
EP2178553A1 (de) 2010-04-28
JP2010533660A (ja) 2010-10-28
US20130102656A1 (en) 2013-04-25
US20100261657A1 (en) 2010-10-14
JP5584618B2 (ja) 2014-09-03

Similar Documents

Publication Publication Date Title
US20240173287A1 (en) Application Of PI4KIIIA Protein And Related Membrane Protein Complex In Treating Alzheimer's Disease
US9655947B2 (en) Use of a granulin or a granulin-like compound for the therapy or prophylaxis of chronic pain
JP2020010707A (ja) ｓｎｏＲＮＡ、組成物、及び使用
US11236378B2 (en) Method for screening drug and therapeutic targets used for treating Alzheimer's disease
Chen et al. Novel and unexpected functions of zebrafish CCAAT box binding transcription factor (NF-Y) B subunit during cartilages development
Logan et al. Deletion of an enhancer that controls Wnt gene expression following tissue injury produces increased adipogenesis in regenerated muscle
US20100112600A1 (en) Methods and compositions for modulating synapse formation
Chuang et al. The zebrafish homeobox gene irxl1 is required for brain and pharyngeal arch morphogenesis
US20190381135A1 (en) Compositions and Methods for Spinal Cord Regeneration
CN115671287B (zh) Feingold综合征Ι型治疗药物及其应用
KR102927985B1 (ko) 병인성 비멘틴과 감염병 동반 악화 강직성척추염 질환 약물개발 모니터링 플랫폼
KR102916085B1 (ko) 뇌전증 관련 불안 장애에 대한 치료 표적 및 치료용 바이오 마커로서 il-17a의 용도
US20250319139A1 (en) Methods for treating neuroinflammation
KR101499299B1 (ko) Ｓｈａｎｋ2 유전자가 결실된 자폐증 모델 형질전환마우스 및 그 용도
Tang et al. p53 peptide prevents LITAF-induced TNF-alpha-mediated mouse lung lesions and endotoxic shock
NZ577564A (en) Angiogenesis affecting polypeptides, proteins, and compositions, and methods of use thereof
KR20220050532A (ko) 기억 유연성이 향상된 마우스 및 이의 용도
Shimizu et al. The Calcineurin-FoxO-MuRF1 signaling pathway regulates myofibril integrity in
Richman CHARACTERIZING THE EXPRESSION AND FUNCTION OF MESENCEPHALIC ASTROCYTE-DERIVED NEUROTROPHIC FACTOR IN CAENORHABDITIS ELEGANS
Ladha Impact of caspase-6 modulation on Huntington disease phenotypes in the YAC128 mouse model
JP2006509795A (ja) インスリンシグナル伝達調節異常と関係する症状の処置方法
JP2009034101A (ja) 神経化誘導に関与する新規遺伝子、およびそのタンパク質、並びにその利用方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130620

MKLA Lapsed

Effective date: 20200831